This website is for UK Healthcare Professionals only

Expert Perspectives

Clear Horizons

The Clear Horizons series provides expert insights and discussion on hot topics in the treatment and clearance of psoriasis.

Skin of Colour

Expert commentary on the importance of understanding how inflammatory skin conditions present in skin of colour, with Dr Laura Savage and Dr Mary Sommerlad.

Treat to Target

Expert discussion on the importance of assessing the impact of psoriasis on patients’ quality of life and defining treatment goals tailored to their needs and lifestyles, with Dr Sandy McBride and Hannah Lakin.

Getting Under the Skin with SKYRIZI

The Getting Under the Skin with SKYRIZI series illustrates, through diverse case studies, psoriasis patient experiences and provides clarity on how therapy can be tailored to their specific treatment goals and lifestyle needs.

Dr Thomas King - Dressed for Winter in Summer

Dr Thomas King - The 78-Year-Old Man

Dr Keith Wu and Pauline Stopford-Taylor - The York Experience

After severe psoriasis impacted her choice of clothing, relationships, and mood for many years, a 34-year-old female patient experiences skin clearance with SKYRIZI.

SKYRIZI allows an older male patient to regain optimism about achieving durable skin clearance after multiple unsuccessful treatments and 48 years of being affected by psoriasis.

Dr Keith Wu and Pauline Stopford- Taylor revisit their experience setting up a specialist service in York. They also illustrate the convenience in dosing and impact of SKYRIZI by sharing their treatment journey with a patient whose psoriasis of the hands was affecting his ability to act as a primary carer for his wife.

Lucy Moorhead - The Global Worker

Lucy Moorhead - The Psoriasis Patient with Co-morbidities

Lucy Moorhead - The Young Footballer

Due to his successful psoriasis treatment with SKYRIZI and its convenient administration, a 37-year-old male patient travels the world and undertakes an international work placement in New York.

A 53 year old male with comorbidities affected by chronic plaque psoriasis since 1981, achieves skin clearance with SKYRIZI and participates in activities such as photography, socialising, and walking.

After two years of unsuccessful treatment, a 29-year-old male patient switches to SKYRIZI, clears his facial and scalp psoriasis, and regains the confidence to play football with his friends.

Clear Horizons TV Q&A Videos

Raising the standard of care via treating to target with early and effective intervention

SKYRIZI efficacy

The simplicity of SKYRIZI dosing and delivery

How to choose the right treatment for the right patient

SKYRIZI in Psoriatic Arthritis

Dr Laura Savage discusses the results of KEEPsAKE 1 and 2 clinical trials

How SKYRIZI works in 3 minutes

Adverse events should be reported. Reporting forms and information can be found at or via the MHRA Yellow Card app, available in the Google Play
or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]


  1. SKYRIZI Summary of Product Characteristics.

UK-RISN-230047. Date of preparation: March 2023. 

SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
Some patients may not be suitable for SKYRIZI. You are advised to read the Prescribing Information (which can be found on tab above). Please also refer to the SKYRIZI Summary of Product Characteristics for important information including special warnings/precautions for use and summary of adverse reactions.
Study design information can be found on the Study Design page.

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to AbbVie on [email protected]